Drug intelligence / Profile preview

Pariet S

Development stage: Unknown
Lead developer: Eisai
Modality: Small Molecules
Administration: Oral

Overview

Pariet S is an over-the-counter (OTC) proton pump inhibitor (PPI) developed by Eisai Co., Ltd. for the Japanese market. It contains rabeprazole sodium, a small molecule that inhibits the H+/K+-ATPase enzyme (the proton pump) in the gastric parietal cells, thereby suppressing stomach acid production. Originally developed as a prescription medication (Pariet), Pariet S was approved in Japan as an RX-to-OTC switch for the relief of stomach pain, heartburn, and bloating. It is designed as a small, easy-to-swallow tablet for once-daily administration, providing 24-hour acid suppression. It represents the first OTC proton pump inhibitor available in Japan.

Brand names: Pariet S

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Pariet S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pariet S.

Explore the full profile